The made-in-Italy fast-track acceleration program dedicated to projects in life science

ZCube, Research Venture of the pharmaceutical group Zambon, announced the second edition of Open Accelerator, the made-in-Italy fast track acceleration program dedicated to projects in life science fields. Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that following a selection could receive a seed investment of up to a maximum of 100.000 EUR for each project.

The call for ideas is open until 16 July 2017 and it covers four main areas of interest:

  • Drug delivery systems (systems that allow better drug delivery either through particles or devices);
  • Open source prototyping: medical devices, biomarkers, diagnostics (Instruments and devices that allow safe and effective treatment, rehabilitation, prevention and diagnosis of diseases);
  • Wearables and digital health (technological solutions through wearable devices that improve the cure of diseases; technological platforms or mobile applications that offer new solutions to improve patient's health)
  • Big data (projects related to the data analysis and solutions to improve medical treatment, develop personalized medicine, identify new markers for early diagnosis and that reduce healthcare costs).

"For many years ZCube has been committed to developing partnerships in the field of scientific research through an open approach which aims at establishing relationships with international researchers, centers of excellence and universities around the world," declares Elena Zambon, President of Zambon Spa. "Open Accelerator is an evolution of ZCube created to sustain scientific and digital innovation, the latter being a great agent of change of our times especially in the healthcare sector."

The program is available through the website http://www.openaccelerator.it. A maximum of 30 projects will be selected to participate in the acceleration program that offers training andsupport by mentors and specialized advisors, including entrepreneurs, business angels, venture capitalists and experts from different areas.

The acceleration path is open to researchers and scientists that have the ambition to conduct translational science. The program will be based on the established methodology of the Business Model Canvas that has been adopted by the National Science Foundation (NSF) and the National Institute of Health (NIH) in the United States.

Moreover, ZCube has recently signed a partnership with IAB - Italian Angels for Biotech, the first association of business angels exclusively dedicated to Life Sciences- and Innogest, a leading venture capital fund operating in Italy and in Europe. Advisors from IAB and Innogest, along with other international experts, will participate in the acceleration path providing mentorship and advisory to guide startuppers through the business model creation and and go-to-market strategy development. At the end of the program the most innovative ideas could receive a seed investment of up to Euro 100.000, which will serve as an important catalyst to enter the market.

"Open Accelerator is an arena in which researchers and entrepreneurs are helped to build the foundation of their startups and to prepare for the challenge of reaching out to venture capital that will finance the next stages of their projects," concludes Elena Zambon. "Our accelerator program will become the heart of Open Zone, the scientific campus located near Milan where science oxygenates business. Open Zone is a community of 600 people where new projects, talents and proven expertise come together to help affirming the role of Italy as an ideal country for business innovation."

For further information and to apply, please visit:
http://www.openaccelerator.it

About ZCube Research Venture Zambon Group
For over a decade ZCube has been active in the exploration of innovative technologies with a profile of technology scouting & brokerage at international level. With an experienced team and network of entrepreneurs, business angels and venture capital, ZCube invests in- and supports innovative ideas from early stages of development up to market launch in the fields of drug delivery, medical devices and digital health. ZCube uses a satellite "open source" research model developed by Zambon in order to develop specialized and innovative products in the areas of the company’s therapeutic interest through collaborations with biotech companies, international research centers and universities.

About Open Zone
Open Zone is a scientific campus near Milan with over 7500mq of laboratories and offices 15.550mq, hosting 22 companies operating in the field of biotechnology and Life Sciences. Open Zone is a place where knowledge is shared amongst multiple partners in the life science to foster innovation, synergy and shared development as well as a place aimed at fostering the development of relationships with the community at large. Open Zone is also home to the Museum Zambon and Oxy.gen, a futuristic air-bubble shaped building created from an idea of the Zambon Group and designed by the architect Michele De Lucchi as a place of science associated with breathing.

About Zambon
Zambon is a leading Italian pharmaceutical and fine-chemical multinational company that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and women’s health, and is very strongly committed to its entry into the CNS space with Xadago® (safinamide) for the treatment of Parkinson’s disease and rare diseases with Promixin® in cystic fibrosis. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 19 countries with subsidiaries and almost 2,800 employees with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 84 countries.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...